What in-house vaccine titering means for veterinary practice

In-house vaccine titering is moving from a niche preventive-care offering toward a more visible part of general practice, as dvm360’s recent coverage and Vet Blast podcast discussion frame point-of-care testing as a way to individualize revaccination decisions and strengthen client communication. The conversation, featuring Adam Christman, DVM, MBA, with Hunter Finn, DVM, and Noga Schiller, DVM, reflects a broader shift in companion animal medicine: more clinics are asking whether some patients need a booster today, or whether an antibody check can answer that question first. (dvm360.com)

That shift didn’t come out of nowhere. Over the past two decades, major vaccination guidelines have steadily moved away from blanket annual revaccination for core canine viral diseases and toward longer intervals, risk stratification, and more careful interpretation of immune status. AAHA’s 2022 canine vaccination guidelines discuss how practitioners can use serology to interpret immune status, particularly for core viral diseases, while WSAVA’s 2024 global guidelines reiterate that every dog and cat should receive core vaccines, but only as frequently as necessary to provide lifelong protection. In other words, the profession has already accepted the principle of avoiding unnecessary vaccination; the current question is how point-of-care titering fits into that principle in real clinics. (aaha.org)

The strongest use case remains core viral disease assessment, especially in dogs. AAHA notes the greatest general-practice interest has been in titers for canine distemper virus, canine parvovirus, and, to a lesser extent, canine adenovirus, because these are serious diseases with highly effective vaccines. The same guideline also cautions that titers can be difficult to interpret because of assay variability, limited standardization across laboratories, and the fact that antibody levels alone don’t fully predict clinical protection in every patient. That nuance matters as clinics consider in-house testing: a titer is a useful data point, not a standalone verdict. (aaha.org)

Recent published evidence supports that some point-of-care assays can be clinically useful, but not perfectly so. A 2023 study in The Veterinary Journal comparing a point-of-care assay with reference hemagglutination inhibition and virus-neutralization methods in 92 dogs found high sensitivity for detecting protective antibody titers against canine distemper, parvovirus, and adenovirus. At the same time, the assay produced false classifications, especially for distemper, underscoring that a positive in-clinic result may be better at ruling out the need for revaccination in some contexts than at serving as an absolute measure of protection. That aligns with the dvm360 framing: in-house titering may improve decision-making, but it doesn’t eliminate the need for clinical judgment. (pubmed.ncbi.nlm.nih.gov)

Industry messaging has pushed the category further by promoting in-clinic platforms such as VacciCheck, and manufacturer-linked materials emphasize convenience, same-visit decision-making, and preventive-care differentiation. But the independent literature is more measured than the marketing. AAHA explicitly says routine titer testing to decide whether to revaccinate at currently recommended intervals is not usually advised for all dogs. Instead, it points to more selective use, including patients with prior adverse vaccine responses, suspected vaccine-related autoimmune disease, or situations where a pet parent is hesitant and a serologic result may help guide the conversation. (biogal.com)

Why it matters: For veterinary professionals, the operational value of in-house vaccine titering may be greatest in three areas: personalization, communication, and retention. Personalization matters for patients with complex histories, uncertain vaccine records, or prior vaccine concerns. Communication matters because a visible, same-day test can give pet parents a concrete basis for discussing boosters instead of forcing an abstract risk-benefit debate. Retention matters because clinics can position titering as part of preventive medicine rather than as an anti-vaccine alternative. Still, practices will need clear protocols on which diseases they’ll test for, how they’ll document interpretation, and how they’ll explain limitations, especially since rabies titers are not accepted in the US as a substitute for required rabies vaccination. (aaha.org)

There’s also a species and workflow question. The evidence base and guideline discussion are more developed for canine core viral diseases than for every feline antigen or every non-core vaccine. WSAVA continues to separate core from non-core vaccines based on lifestyle and regional risk, which means titering is unlikely to become a one-size-fits-all substitute for protocol-based preventive care. For most practices, the near-term opportunity is probably narrower and more practical: using validated in-house titers in selected canine and feline cases, integrating them into wellness and vaccine consults, and avoiding overpromising what a result can mean. (wsava.org)

What to watch: The next phase will likely center on assay validation, clinic adoption economics, and whether future AAHA, AAFP, or WSAVA updates offer more explicit guidance on which patients benefit most from point-of-care titering, and where the evidence still falls short. (pubmed.ncbi.nlm.nih.gov)